FDA Posts Briefing Documents for Advisory Committee Meeting to Review Kyndrisa™ (drisapersen) for the Potential Treatment of Duchenne Muscular Dystrophy Amendable to Exon 51 Skipping
20 nov. 2015 08h10 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the U.S. Food and Drug Administration (FDA) posted briefing materials...
Ernst & Young Names BioMarin CEO Jean-Jacques Bienaime EY Entrepreneur Of The Year® 2015 National Award Winner in Life Sciences
16 nov. 2015 08h00 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Ernst & Young Global Limited awarded BioMarin CEO Jean-Jacques Bienaimé...
BioMarin Announces Third Quarter 2015 Financial Results and Company Update
29 oct. 2015 16h03 HE
|
BioMarin Pharmaceutical Inc.
- Vimizim Net Product Revenue $65 million in the Quarter; Vimizim Full-year Revenue Guidance Increased to $220 to $235 million - Full-year Total BioMarin Revenue Guidance Increased to $880 million...
BioMarin to Attend Upcoming Investor Conference in November
27 oct. 2015 08h30 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate...
BioMarin to Host Third Quarter 2015 Financial Results Conference Call and Webcast on Thursday, October 29 at 4:30pm ET
15 oct. 2015 16h05 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
BioMarin Announces FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
15 oct. 2015 07h54 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S....
BioMarin’s Initial 6-Month Data From Phase 2 Study of Vosoritide (BMN 111) in Children With Achondroplasia Presented at the American Society for Bone and Mineral Research Annual 2015 Meeting
12 oct. 2015 16h30 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dr. Melita Irving, Clinical Geneticist, Guy's and St Thomas’ NHS...
BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
01 oct. 2015 03h30 HE
|
BioMarin Pharmaceutical Inc.
Strengthens and Expands BioMarin's Leadership Position Serving PKU Patients with Rights to Both Kuvan® (sapropterin dihydrochloride) and Pegvaliase Beyond North America
2016 Full-year...
BioMarin to Present Research Results on Duchenne Muscular Dystrophy and Pompe Disease Programs at the 20th International Congress of the World Muscle Society
30 sept. 2015 16h06 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company will present research results at the 20th International Congress of...
BioMarin Receives Favorable Ruling in the Use of Exon 51 Antisense Oligonucleotides Patent Interference
29 sept. 2015 18h10 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Patent Trial and Appeal Board (PTAB) issued a decision in favor of BioMarin's...